Publicaciones en colaboración con investigadores/as de University of Calgary (4)

2022

  1. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

    Blood, Vol. 140, Núm. 8, pp. 839-850

2020

  1. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study

    Journal of Clinical Oncology

2018

  1. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia

    New England Journal of Medicine, Vol. 378, Núm. 12, pp. 1107-1120

2014

  1. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions

    New England Journal of Medicine, Vol. 370, Núm. 12, pp. 1101-1110